INTRODUCTION
The childhood neuronal ceroid lipofuscinoses (NCLs) are a group of recessively inherited neurodegenerative disorders associated with progressive visual impairment, seizures, motor disturbances, dementia and premature death. There is characteristic accumulation of autofluorescent lipopigment in neurons and other cell types. Based on differences in clinical phenotype and the ultrastructural morphology of the stored material in cells, three main childhood NCL subtypes are recognized which have an infantile, late-infantile or juvenile age of onset. Ultrastructural examination of the stored material shows that granular osmiophilic deposits (GROD) are characteristic of the infantile subtype, while the late-infantile and juvenile subtypes are distinguished by curvilinear bodies and mixed curvilinear and fingerprint bodies, respectively (1, 2) . A number of 'variant' subtypes have also been reported (3) (4) (5) (6) (7) (8) . Three of the corresponding genes have been cloned. These are CLN1, the gene for infantile NCL (INCL) which encodes palmitoyl-protein thioesterase (PPT) (12) , CLN2, the gene for classical late-infantile NCL (LINCL) which encodes a pepstatininsensitive protease (13) , and CLN3, the gene for juvenile NCL (JNCL) which encodes a novel protein of unknown function (14) .
One variant subtype of NCL, first described in 1973 (6, 15) , is distinct in having a juvenile age of onset but an ultrastructural characterization that is unique to the infantile subtype, i.e. GROD without curvilinear or fingerprint bodies. This variant is designated vJNCL/GROD. The clinical characteristics of vJNCL/ GROD patients that have been documented (6, (16) (17) (18) (19) (20) (21) (22) (23) and those reported here are quite variable but resemble juvenile onset NCL more closely than any other subtype. However, presentation can be with learning rather than visual difficulties in the latter half of the first decade. Visual failure soon follows and subsequent regression can be severe with progression to a vegetative state. Seizures commonly develop in the latter half of the second decade. The vJNCL/GROD variant, however, is like INCL rather than JNCL in other respects. Patients show no accumulation of subunit c of mitochondrial ATP synthase in their stored material which is a characteristic feature of JNCL (24) . In addition, vacuolated lymphocytes in peripheral blood which are typical of JNCL are not documented in INCL or in vJNCL/GROD except in one unsubstantiated report (23) . Storage of saposins in the stored material is a feature of NCL (25) and recent investigation has revealed that in vJNCL/GROD the storage is at levels more consistent with INCL than JNCL (B.D. Lake and J. Tyynela, unpublished data).
Previous work has shown that vJNCL/GROD is not linked to the CLN3 locus at 16p12 (26) . The similarities between vJNCL/GROD and INCL have raised the possibility that defects in the CLN1 gene PPT could underly both diseases (22, 23, 26) . Preliminary genetic linkage analysis in a group of four vJNCL/ GROD families showed support for linkage to the CLN1 locus although statistically significant evidence of linkage was precluded by the limited family resource (26) . Linkage analysis on an expanded resource of 11 vJNCL/GROD families in this study supports linkage to the CLN1 locus. Mutations were subsequently characterized in the PPT gene and the disease alleles in 10 vJNCL/GROD families have been identified.
RESULTS

Linkage analysis of vJNCL/GROD at the PPT (CLN1; INCL) locus
Eleven vJNCL/GROD families were used in genetic linkage analysis at the PPT (CLN1; INCL) locus on chromosome 1p32. This includes four families (54, 56, 105 and 173) used in the previous linkage study (26) . The clinical features of the disease in each family are described in Table 1 and pedigree structures are shown in Figure  1a . All members of the vJNCL/GROD families were typed with markers which have the following order:
Pairwise lod scores between vJNCL/GROD and each marker are shown in Figure 1b . No recombination was observed between vJNCL/GROD and marker D1S211 and a maximum pairwise lod score of 2.63 (θ = 0.00) was obtained. The size of the current family resource is too small to provide statistically significant linkage results at this marker, since three families (325, 345 and 346) provide no information. 
Mutations disrupting PPT (CLN1; INCL) underlying vJNCL/GROD
Following positive linkage results all nine exons of the PPT gene were amplified and sequenced in 11 vJNCL/GROD probands in order to look for mutations. Primer sets are detailed in Table 2 . Five novel PPT mutations were identified: three missense mutations and two nonsense mutations predicted to give rise to truncated proteins (Table 3 , Fig. 2 ). The predicted missense mutation Asp79Gly, present in proband 208, is located at the splice acceptor site of exon 3 and is due to transition of the second nucleotide of the exon (position 236) from an A to a G. RT-PCR amplification of fibroblast cell mRNA from the proband in family 208 was performed using primers in exon 2 and 6. Exons 2-6 were found to be correctly spliced indicating that the Asp79Gly mutation does not affect splicing of exon 3 (data not shown). Only the Asp79Gly mutation was observed, indicating that the nonsense mutation in exon 5 (Arg151STOP) did not amplify. This suggests that the Arg151STOP mutation causes message instability leading to a 'null' allele. For each of the five mutations, inheritance in family members was checked by use of a restriction-digest test where available, or sequencing, and the results are presented in Table 3 . Mendelian inheritance of the mutations was observed in all family members. None of the missense mutations were observed in 90 or more chromosomes of unaffected control individuals, indicating that they are likely not to be polymorphisms. No mutations were detected in any of the nine PPT exons and surrounding sequence in the proband in family 336.
Defective PPT (CLN1; INCL) activity in vJNCL/GROD patients
PPT activity was measured in cytosolic extracts of immortalized peripheral blood lymphocytes (PBL) from members of three vJNCL/GROD families and compared with activities from normal, JNCL and INCL extracts. In this experiment (Table 4) , one normal and two JNCL patients had normal PPT activity as compared with a reference range for nine normal controls established in the laboratory [0.93 ± 0.09 (SE) pmoles of palmitate released/min/mg of protein]. In contrast, the vJNCL/ GROD patients had severely reduced activity that was indistinguishable from a reference group of nine typical US INCL patients [0.103 ± 0.02 pmol/min/mg (S. Hofmann and C. Becerra, unpublished data)]. No significant differences in PPT activity were observed amongst vJNCL/GROD patients with different PPT mutations. As expected, obligate heterozygotes had values of activity that were approximately half of those of normal controls. Immunoblotting of the cytosolic extracts of vJNCL/ GROD patients showed severely reduced levels of PPT protein, although the high background of these immunoblots prevented accurate quantitation of the amount of residual PPT, if any (data not shown). 
DISCUSSION
Genetic linkage and subsequent mutational analysis presented here provides convincing evidence that PPT defects underly vJNCL/GROD. Mutations in the PPT gene have been identified on both chromosomes in all vJNCL/GROD patients except the proband in family 336. Restriction-digestion tests have been developed for the majority of the mutations characterized and this will be important for diagnosis of vJNCL/GROD in patients and carriers.
A total of five mutations in the open reading frame of PPT have been characterized. In the group of 11 vJNCL/GROD families there is discernible sharing of common mutations. The missense mutation Thr75Pro and nonsense mutation Arg151STOP are particularly common, occurring on nine and seven of the 22 disease chromosomes analysed, respectively. The nonsense mutation Leu10STOP is found on two disease chromosomes. This implies that there is a common ancestry amongst the vJNCL/GROD families, as has been reported in the other forms of NCL (11, (27) (28) (29) (30) . Eight families (28, 54, 56, 105, 325, 341, 345 and 346) from the UK and North America share the mutations Thr75Pro, Arg151STOP and Leu10STOP. Five of these families are from Scotland, which is likely to contribute to this association (23) . Only three families do not carry the common Thr75Pro mutation: family 208, which is of Hispanic origin and therefore the only non-Caucasian family, carries Arg151STOP and the single missense mutation Asp79Gly; family 173, from Belgium, carries Arg151STOP and the other single missense mutation Leu219Gln; family 336 carries none of these mutations. The sharing of mutations in vJNCL/GROD is striking; however, the small number of chromosomes under investigation together with the presence of common alleles at adjacent genetic loci preclude identification of statistically significant linkage disequilibrium.
The majority of the vJNCL/GROD patients are compound heterozygotes for a nonsense mutation in conjunction with a missense mutation. Family 56 is the only exception and the affected children each carry two copies of the missense mutation Thr75Pro. The nonsense mutations found in vJNCL/GROD are predicted to abolish PPT enzyme function. The Arg151STOP nonsense mutation results in no expression of the PPT mRNA, and since the other nonsense mutation Leu10STOP occurs earlier in the open reading frame it is predicted to have a similar consequence. Missense mutations in vJNCL/GROD which are found in conjunction with either nonsense mutation must have a less marked effect on function since vJNCL/GROD has a later onset and more protracted course compared with the severe infantile disease. Homologues of PPT have been described in cattle, rat and Caenorhabditis elegans (accession nos P45478, P45479 and U50313). The amino acid residues altered in vJNCL/GROD missense mutations affect PPT amino acid residues that are completely conserved (Asp79Gly and Leu219Gln) or conserved in residue type (Thr75Pro) across all species, suggesting that they are functionally important.
Results described in this paper confirm that vJNCL/GROD is allelic to INCL. However, none of the PPT mutations reported in INCL occurs in vJNCL/GROD and the two diseases each appear to be due to a distinct spectrum of mutations. Three mutations have been reported to date to cause INCL: a missense mutation Arg122Trp which is located immediately adjacent to the putative active-site serine, a mutation leading to a null allele and a nonsense mutation Lys55STOP [(12), Fig. 2 ]. The combination of Arg122Trp on both chromosomes or Arg122Trp in combination with the null allele mutation give rise to INCL. These mutations are all predicted to abolish thioesterase activity and this has been shown to be the case with the Arg122Trp mutation (12, 31) .
Of the three missense mutations characterized in vJNCL/ GROD, none is located close to the active site of PPT and presumably sufficient enzyme function is preserved to delay disease onset in comparison with INCL (12, 32) . This situation is similar to that seen in JNCL where the typical JNCL phenotype arises in patients homozygous for nonsense mutations and a milder phenotype is observed in compound heterozygotes carrying a nonsense in conjunction with a missense mutation (33) . It remains to be seen by what mechanism the presence of the Thr75Pro missense mutation on both chromosomes (patient 56) leads to a similar clinical course of disease as a nonsense mutation in conjunction with the same missense mutation (e.g. patient 54). The effect of mutations on biochemical activity of PPT will be clarified in subsequent work, for example by analysis of transient expression of mutant versus wild-type cDNA constructs in cells as was done by Vesa et al. (12) . If the disease in family 336 is due to PPT defects they must lie outside the open reading frame, for example in the regulatory region, and further mutation screening is needed. Unfortunately, no material suitable for testing PPT activity was available for this family.
PPT enzyme activity is clearly greatly reduced in vJNCL/ GROD when assayed in lymphocyte cells derived from patient peripheral blood. A statistically significant difference between the low levels of PPT activity observed in PBLs in vJNCL/GROD and INCL was not apparent. However, there are limitations to quantitative testing of thioesterase activity in this cell type and estimation in brain tissue where PPT expression is higher (12, 34) may reveal subtle differences. In enzyme deficiencies small differences in residual enzyme activity can make the difference between a mild and severe phenotype as has been noted, for example, in Gaucher's disease where glucocerebrosidase levels overlap in the different disease types (35, 36) . In vJNCL/GROD even slightly raised levels of PPT activity could have a significant effect on the clinical course. Defects in PPT enzyme activity have also been reported in a variant of late-infantile NCL with GROD although the corresponding mutations have not yet been isolated (37) .
The results presented in this study demonstrate that PPT mutations underly vJNCL/GROD and they provide further evidence to that presented by Sharp et al. (8) of the close correlation between ultrastructural changes and underlying molecular genetic basis in this group of diseases.
MATERIALS AND METHODS
Patient samples
DNA samples from 11 unrelated families which all fit the diagnostic criteria of vJNCL/GROD were used in this study ( Table 1 ). The families originated from five different countries: the UK (England and Scotland), USA, Belgium, The Netherlands and Newfoundland. Genomic DNA was extracted from peripheral blood or peripheral blood lymphoblastoid cell lines (PBLs).
Linkage analysis
Family members were genotyped as described previously (8) using fluorescently labelled markers selected from those listed in the Genome Database (GDB); primer sets were supplied by Research Genetics and Genset. Map information for D1S255, HY-TM1, PPT and D1S211 was kindly provided by Dr E. Hellsten and the distance to D1S200 was obtained from GDB. Linkage analysis was carried out using LINKAGE version 5.2 (38) . Fully penetrant autosomal recessive inheritance and a disease allele frequency of 0.001 was assumed. Pairwise lod scores were calculated using the LODSCORE and MLINK options.
PCR amplification of exons and direct sequencing
Primers that amplify each exon and its surrounding intron sequence were designed from genomic DNA sequence of PPT [accession no. L42809 (39) ]. Since publication of the PPT genomic structure, a new intron within exon 4 has been determined and there are now nine exons in PPT which have been renamed 1-9 accordingly. The large final exon, exon 9, was amplified in five segments which encompass the polyadenylation site. Novel sequences generated in order to design primers can be found in GDB, accession nos AF022203-AF022211. PCR was performed in a final volume of 50 µl with 100 ng of genomic DNA, 0.2 µM of each primer, 0.25 mM of each dNTP, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl 2 and 1.5 U of Taq DNA polymerase (Gibco/BRL). A 'hot' start was usually performed, followed by 30 cycles of 1 min at 94_C, 1 min at 56-60_C (dependent on the primer set) and 1 min at 72_C followed by 10 mins at 72_C, on a Hybaid Omnigene. The resulting products were electrophoresed in 2% agarose gels and visualized after ethidium bromide staining on a UV transilluminator. Amplified products were desalted and concentrated on Microcon-100 columns (Amicon) for direct sequencing. Sequencing was performed using Taq FS (Perkin-Elmer) and a 373A Applied Biosystems automatic sequencer, as previously described (33) .
Restriction endonuclease analysis
Amplified exons were digested with the relevant endonuclease according to the manufacturer's recommendations. Samples were electrophoresed on 2% agarose gels and visualized after ethidium bromide staining on a UV transilluminator.
RNA extraction and analysis
Cytoplasmic mRNA was isolated from a skin fibroblast cell line generated from the proband in family 208 and RT-PCR performed as previously described (33) with exon 2 forward primer 5′-TCCCTTAAGCATGGGTGCTA-3′ and exon 6 reverse primer 5′-TCTGCCAAGAAGATGCTGTG-3′.
Analysis of PPT activity
Assays for palmitoyl-protein thioesterase activity were performed on extracts of PBLs as described (40) with the exception that a crude cytosolic fraction (100 000 g supernatant) of lymphoblasts was prepared. The samples were preincubated in the presence of 2.0 mM phenylmethanesulphonyl fluoride for 40 min at 37_C to reduce non-specific thioesterase activity, and the assays were carried out for 90 min at 37_C. The specific activity of the [ 3 H]palmitate labelled H-Ras substrate was 331 cpm/pmol. PBLs from each individual were assayed four times with the exception of proband 28 and JNCL control L61Pa, which were assayed two and three times, respectively, due to lack of material. Immunoblotting was performed as described previously (41) .
